Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated With Adjuvant Nivolumab
Urologia Internationalis · 05.10.2026 · 1-1
DOI: 10.1159/uin/aewag032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Urologia Internationalis, online erschienen am 05.10.2026. Verfasst von Asuka Sano und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan, kwkmask@hama-med.ac.jp. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Introduction
Adjuvant nivolumab prolongs disease-free survival (DFS) after radical surgery for high-risk urothelial carcinoma (UC), yet recurrence remains common. We investigated the prognostic impact of clinical and systemic inflammatory factors in these patients.
Methods
We retrospectively analyzed 127 patients who received adjuvant nivolumab following radical surgery at six institutions between April 2022 and January 2026. Prognostic factors for DFS were evaluated using Cox proportional hazards regression models.
Results
The median follow-up was 12.0 months, and DFS events occurred in 43.3% of patients. In the multivariable analysis, advanced pathological T stage (pT3–4 vs. pT1–2) (hazard ratio [HR], 2.525; 95% CI, 1.067–5.979) and baseline neutrophil-to-lymphocyte ratio (NLR) (HR, 1.216 per 1 unit increase; 95% CI, 1.034–1.430; p = 0.018) emerged as independent predictors of inferior DFS. Additionally, female sex showed an independent association with shorter DFS (HR, 0.275; 95% CI, 0.152–0.495; p < 0.001, though this finding warrants cautious interpretation given baseline characteristics and the small proportion of female patients.
Conclusion
Baseline NLR and advanced pT stage serve as valuable independent prognostic factors for patients receiving adjuvant nivolumab. Although interpreted with caution regarding specific subgroups and retrospective limitations, these findings highlight key risk factors in this setting and provide a rationale for larger prospective validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan, kwkmask@hama-med.ac.jp.
- Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Urology, Kawasaki Medical School, Kurashiki, Japan.
- Department of Urology, Fujita Health University, Toyoake, Japan.
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
Zitieren
APA
Sano, A., Oishi, Y., Ishikawa, G., Watanabe, S., Watanabe, S., Tsuchiya, Y., Maenosono, R., Yoshikawa, Y., Nishio, K., Morinaka, H., Saruta, M., Fukuokaya, W., Watanabe, K., Watanabe, H., Tamura, K., Motoyama, D., Yanagisawa, T., Takahara, K., Yamamoto, Y., …, & Inamoto, T. (2026). Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated With Adjuvant Nivolumab. Urologia Internationalis, 1-1. https://doi.org/10.1159/uin/aewag032
Vancouver
Sano A, Oishi Y, Ishikawa G, Watanabe S, Watanabe S, Tsuchiya Y, et al. Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated With Adjuvant Nivolumab. Urologia Internationalis. 2026:1-1. doi:10.1159/uin/aewag032
BibTeX
@article{Sano2026,
author = {Sano, Asuka and Oishi, Yuya and Ishikawa, Gaku and Watanabe, Shunsuke and Watanabe, Shinya and Tsuchiya, Yoshihiro and Maenosono, Ryoichi and Yoshikawa, Yuki and Nishio, Kyosuke and Morinaka, Hirofumi and Saruta, Masanobu and Fukuokaya, Wataru and Watanabe, Kyohei and Watanabe, Hiromitsu and Tamura, Keita and Motoyama, Daisuke and Yanagisawa, Takafumi and Takahara, Kiyoshi and Yamamoto, Yutaka and Fujita, Kazutoshi and Inamoto, Teruo},
title = {Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio and Clinicopathological Factors in a Multicenter Cohort of Urothelial Carcinoma Treated With Adjuvant Nivolumab},
journal = {Urologia Internationalis},
year = {2026},
pages = {1--1},
doi = {10.1159/uin/aewag032}
}
EUVIMED